Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Rallied Today

By Joe Tenebruso – Aug 17, 2021 at 6:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new regulatory authorization and a potentially soon-to-be-announced plan for booster shots drove investors to ramp up their purchases of the popular biotech stock.

What happened 

Shares of Moderna (MRNA 1.59%) climbed 7.5% on Tuesday after health officials in the U.K. approved the drugmaker's COVID-19 vaccine for children ages 12 to 17. 

So what

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a conditional approval for Moderna's vaccine, now called Spikevax, based on clinical trials that showed the drug to be safe and effective in kids 12 years of age and older. 

A healthcare professional is administering a vaccine to a teenager.

Image source: Getty Images.

The news comes as COVID-19 case counts are rising at an alarming clip in many areas of the world, driven by the spread of the highly contagious Delta variant. Health officials hope the vaccine will help to reduce the spread of the disease when students return to school in the coming weeks.

Now what

Additionally, U.S. health regulators are reportedly planning to authorize booster shots for most Americans. The move would allow people who received two doses of Moderna's or Pfizer's coronavirus vaccines to receive a third dose, thereby boosting their ability to fend off the virus. The Biden administration could make the announcement as soon as this week, according to The New York Times

A third round of doses would likely also help to boost Moderna's sales and profits. Investors know this, and they responded to the news by bidding up the vaccine maker's stock price today.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$175.91 (1.59%) $2.76
Pfizer Stock Quote
Pfizer
PFE
$50.13 (1.29%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.